Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Accounts Payables (2016 - 2025)

Perspective Therapeutics' Accounts Payables history spans 15 years, with the latest figure at $13.1 million for Q3 2025.

  • For Q3 2025, Accounts Payables fell 39.72% year-over-year to $13.1 million; the TTM value through Sep 2025 reached $13.1 million, down 39.72%, while the annual FY2024 figure was $10.3 million, 49.7% up from the prior year.
  • Accounts Payables for Q3 2025 was $13.1 million at Perspective Therapeutics, up from $7.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $21.8 million in Q3 2024 and bottomed at $98000.0 in Q2 2021.
  • The 5-year median for Accounts Payables is $3.9 million (2023), against an average of $5.1 million.
  • The largest YoY upside for Accounts Payables was 2104.44% in 2021 against a maximum downside of 85.02% in 2021.
  • A 5-year view of Accounts Payables shows it stood at $847000.0 in 2021, then skyrocketed by 81.94% to $1.5 million in 2022, then surged by 348.35% to $6.9 million in 2023, then skyrocketed by 49.7% to $10.3 million in 2024, then rose by 27.12% to $13.1 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Accounts Payables are $13.1 million (Q3 2025), $7.0 million (Q2 2025), and $8.7 million (Q1 2025).